These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14988769)

  • 21. Sibutramine lost and found.
    Bosello O; Carruba MO; Ferrannini E; Rotella CM
    Eat Weight Disord; 2002 Sep; 7(3):161-7. PubMed ID: 12452247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sibutramine and the management of obesity.
    Poston WS; Foreyt JP
    Expert Opin Pharmacother; 2004 Mar; 5(3):633-42. PubMed ID: 15013931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
    Hazenberg BP
    Cardiology; 2000; 94(3):152-8. PubMed ID: 11279320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of weight reduction by sibutramine on female sexual function.
    Kim KK; Kang HC; Kim SS; Youn BB
    Int J Obes (Lond); 2006 May; 30(5):758-63. PubMed ID: 16404407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
    Kaukua JK; Pekkarinen TA; Rissanen AM
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of sibutramine and dexfenfluramine in the treatment of obesity.
    Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
    Obes Res; 1998 Jul; 6(4):285-91. PubMed ID: 9688105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
    James WP; Astrup A; Finer N; Hilsted J; Kopelman P; Rössner S; Saris WH; Van Gaal LF
    Lancet; 2000 Dec 23-30; 356(9248):2119-25. PubMed ID: 11191537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ..
    Prescrire Int; 2001 Oct; 10(55):140-5. PubMed ID: 11824428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
    Hansen HH; Hansen G; Tang-Christensen M; Larsen PJ; Axel AM; Raben A; Mikkelsen JD
    Eur J Pharmacol; 2010 Jun; 636(1-3):88-95. PubMed ID: 20385125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
    Toubro S; Hansen DL; Hilsted JC; Porsborg PA; Astrup AV;
    Ugeskr Laeger; 2001 May; 163(21):2935-40. PubMed ID: 11402974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of lifestyle modification and pharmacotherapy for obesity.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Phelan S; Cato RK; Hesson LA; Osei SY; Kaplan R; Stunkard AJ
    N Engl J Med; 2005 Nov; 353(20):2111-20. PubMed ID: 16291981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.